Navigation Links
Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
Date:10/26/2010

current therapies.  Zerenex has the potential to be an effective and safe treatment in lowering and/or maintaining normal serum phosphorus levels in patients with ESRD and hyperphosphatemia.

The market for phosphate binders to treat hyperphosphatemia in ESRD patients in 2009 was approximately $750 million and $1.3 billion in the U.S. and worldwide, respectively.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference
3. Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference
4. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
5. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
6. Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma
7. Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
8. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
9. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
11. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... Research and ... of the "Biomedical Photoacoustic Imaging Patent ... This patent landscape focuses on photoacoustic ... safe, non-invasive, non-ionizing imaging technique. The technique ... alternative to traditional medical imaging approaches. The ...
(Date:7/7/2015)... July 7, 2015 Sequent Medical, a ... innovative devices for the treatment of neurovascular disease, ... has joined its Board of Directors.   ... medical device and healthcare industries experience.  He has ... has commercialized numerous leading-edge products.  His experience encompasses ...
(Date:7/7/2015)... 2015 Accelovance, Inc. (Accelovance), a global ... and General Medicine announced the completion of enrollment ... Heron Therapeutics, Inc. for the Phase 3 trial ... candidate SUSTOL® (granisetron injection, extended release) as part ... 1 receptor antagonist fosaprepitant and IV corticosteroid ...
Breaking Medicine Technology:Worldwide Biomedical Photoacoustic Imaging Patent Landscape Report 2015 2Worldwide Biomedical Photoacoustic Imaging Patent Landscape Report 2015 3Sequent Medical Appoints Mike Kleine to its Board of Directors 2Sequent Medical Appoints Mike Kleine to its Board of Directors 3Accelovance Completes Trial Enrollment and Delivery of Clinical Data for Heron Therapeutics' Phase 3 Trial 2
... levels were significantly higher in patients with osteosarcoma than ... Biological Trace Element Research (April 2009). Osteosarcoma, ... young adults.Randhu and colleagues measured serum fluoride levels in ... one had osteosarcoma, group two had non-osteosarcoma bone tumors, ...
... U.S. Agency for International Development (USAID) is convening a ... Ethiopia, in a regional exercise that will kick off ... The three-day exercise seeks to advance global capacity ... a pandemic. As recently emphasized by outbreaks of swine ...
Cached Medicine Technology:Another Study Links Fluoride to Bone Cancer 2USAID Cooperates in Pandemic Preparedness Initiative 2USAID Cooperates in Pandemic Preparedness Initiative 3
(Date:7/7/2015)... ... ... Nigeria – In her new novel, “ A Broken Rose ” (published by Xlibris), ... with abuse, alienation and torture from an impoverished and deeply religious village that stigmatizes ... and in a wealthy suburb of metropolitan Lagos, Nigeria, readers follow a young ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... from Cambridge Consultants that discussed how innovation and technology would be the “key ... need to address issues of accessibility and affordability, especially in emerging and growing ...
(Date:7/7/2015)... ... ... Silverado today issues its first update on construction of a new memory ... site in Bellingham, Washington. Cordata Design Review Board approved design and landscape plans for ... the local community. , The new complex – located at the 4400 block of ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... the Southwest, including Giant, Mustang, Sun Dial and Howdy’s, raised more than ... original 2015 fundraising goal by nearly $100,000, to help support children fighting ...
(Date:7/7/2015)... CA (PRWEB) , ... July 07, 2015 , ... ... Business Times highlights rumors about possible facial rejuvenation that have emerged about Hillary ... former U.S. Secretary of State looks more youthful than she has in some ...
Breaking Medicine News(10 mins):Health News:Uju Amanambu crafts poignant tale depicting woes of mental illness 2Health News:Uju Amanambu crafts poignant tale depicting woes of mental illness 3Health News:Recent Article on Pharmaceutical Innovation Highlights the Need for Creative Solutions to Common Problems, Says Medlife Pharmacy 2Health News:Recent Article on Pharmaceutical Innovation Highlights the Need for Creative Solutions to Common Problems, Says Medlife Pharmacy 3Health News:New Silverado Memory Care Community Receives Unanimous Approval from Design Review Board 2Health News:Western Refining Raises $524,286 to Help Send Kids with Neuromuscular Disease to MDA Summer Camp 2Health News:Western Refining Raises $524,286 to Help Send Kids with Neuromuscular Disease to MDA Summer Camp 3Health News:Recent Article on Hillary Clinton Plastic Surgery Speculation Illuminates the Reasons Many Professionals Explore Facial Rejuvenation, says Dr. J 2Health News:Recent Article on Hillary Clinton Plastic Surgery Speculation Illuminates the Reasons Many Professionals Explore Facial Rejuvenation, says Dr. J 3
... The Association of Public,Health Laboratories (APHL) congratulates ... Hillary Clinton (D-NY), along with Congresswoman Lucille,Roybal-Allard ... the president,signing into law their legislation that ... improved follow-up care and enables states,to improve ...
... HOUSTON Whole-organ maps that superimpose genetic information over ... from normal cell to invasive cancer, an international research ... M. D. Anderson Cancer Center reports online at the ... Group., By geographically relating an organs varied tissues ...
... May 5 Alseres,Pharmaceuticals, Inc. (Nasdaq: ALSE ... a panel entitled "Traumatic Brain and Spinal Cord ... in Boston, MA,Thursday, May 8, 2008. The session ... to the Central Nervous System (CNS). The event ...
... Legal, Regulatory and,Policy Issues, WASHINGTON, May 5 ... States?, That,s a key question that will ... and Challenges, sponsored by the American,Association for the ... Drug Law,Institute (FDLI), June 20, 2008, at AAAS ...
... Against Influenza Observed; Good Protection, Demonstrated in Trial Evaluating ... ... Children, HONOLULU, May 5 Data from two ... Academic Societies (PAS) demonstrate,that FluMist(R) (Influenza Virus Vaccine Live, ...
... Ky., May 5 According to new,research findings ... fails to implement and enforce strong tobacco control ... prematurely from,smoking over just the next fifteen to ... rate in the United States. Kentucky also has ...
Cached Medicine News:Health News:Association of Public Health Laboratories Applauds Signing of Newborn Screening Saves Lives Act 2Health News:Combined physical and genetic map finds cancer's 'ignition key' 2Health News:Combined physical and genetic map finds cancer's 'ignition key' 3Health News:Combined physical and genetic map finds cancer's 'ignition key' 4Health News:Combined physical and genetic map finds cancer's 'ignition key' 5Health News:Alseres Pharmaceuticals, Inc. to Present at The Neurotech Industry Investing & Partnering Conference 2Health News:AAAS, FDLI Sponsor Landmark Meeting on Personalized Medicine June 20, 2008 2Health News:AAAS, FDLI Sponsor Landmark Meeting on Personalized Medicine June 20, 2008 3Health News:Efficacy of FluMist(R) in Children Highlighted at Pediatric Academic Societies Meeting 2Health News:Efficacy of FluMist(R) in Children Highlighted at Pediatric Academic Societies Meeting 3Health News:Efficacy of FluMist(R) in Children Highlighted at Pediatric Academic Societies Meeting 4Health News:Study Suggests Stronger Tobacco Control Policies in States With High Smoking Rates Would be Effective in Reducing Smoking and Saving Thousands of Lives 2Health News:Study Suggests Stronger Tobacco Control Policies in States With High Smoking Rates Would be Effective in Reducing Smoking and Saving Thousands of Lives 3
... Graham-Field has been developing diverse ... 58 years. Our medical-surgical products ... for innovation, quality and customer ... include the Labtron® line of ...
... medication as well as humidification, try Flo-Mist™., ... high volume, continuous medication nebulizer (CMN), engineered ... Its 200 ml reservoir and jet flow ... of nebulized medication delivery at 25 ml/hr. ...
Rotary Piston Nebulizer...
... the exceptional performance you need at a price ... and durability youd expect from headlights priced much ... features our thinnest cable and adjusts from 90 ... when you reach for a headlight you can ...
Medicine Products: